(C) Wolf G Kroner 2010 - Elmar SchneeElmar Schnee Leaves Merck KGaA ... and Chemgenex?

December 2010. The departure of Elmar Schnee, General Partner of Merck KGaA, comes to a surprise. One of his few external positions is with Chemgenex Pharmaceuticals. CXS is expected to launch its OMAPRO competing with Novartis' and BMS' drugs. How will Chemgenex be affected?


If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 3 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Make or Break Drug Discovery and Biopharma of Merck Life Science
Andrew Bulpin, currently Global Head of Merck Millipore Process Solutions on strategy and the road ahead. Includes competitive rank of Merck Life Science Division.

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, today Head of Global Research and Early Development for Merck Serono on stem cell research

Eurofins: Sustainable profitability – albeit not for investors in a hurry

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Triggering Regenerative Functions with Transplanted Cells and Small Molecules
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville

Merck Serono Manufacturing: We have biosimilars coming …
Jonathan Barnsley, Senior Vice President, Biotech Manufacturing & Process Development Merck Serono on peak process performance, alternative technology platforms, and adapting them to industrial scale